Literature DB >> 32312836

MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG.

Sean G Rudd1, Helge Gad1, Kumar Sanjiv1, Nuno Amaral1, Anna Hagenkort1, Petra Groth1, Cecilia E Ström1, Oliver Mortusewicz1, Ulrika Warpman Berglund1, Thomas Helleday2,3.   

Abstract

Reactive oxygen species (ROS) oxidize nucleotide triphosphate pools (e.g., 8-oxodGTP), which may kill cells if incorporated into DNA. Whether cancers avoid poisoning from oxidized nucleotides by preventing incorporation via the oxidized purine diphosphatase MTH1 remains under debate. Also, little is known about DNA polymerases incorporating oxidized nucleotides in cells or how oxidized nucleotides in DNA become toxic. Here we show that replacement of one of the main DNA replicases in human cells, DNA polymerase delta (Pol δ), with an error-prone variant allows increased 8-oxodG accumulation into DNA following treatment with TH588, a dual MTH1 inhibitor and microtubule targeting agent. The resulting elevated genomic 8-oxodG correlated with increased cytotoxicity of TH588. Interestingly, no substantial perturbation of replication fork progression was observed, but rather mitotic progression was impaired and mitotic DNA synthesis triggered. Reducing mitotic arrest by reversin treatment prevented accumulation of genomic 8-oxodG and reduced cytotoxicity of TH588, in line with the notion that mitotic arrest is required for ROS buildup and oxidation of the nucleotide pool. Furthermore, delayed mitosis and increased mitotic cell death was observed following TH588 treatment in cells expressing the error-prone but not wild-type Pol δ variant, which is not observed following treatments with antimitotic agents. Collectively, these results link accumulation of genomic oxidized nucleotides with disturbed mitotic progression. SIGNIFICANCE: These findings uncover a novel link between accumulation of genomic 8-oxodG and perturbed mitotic progression in cancer cells, which can be exploited therapeutically using MTH1 inhibitors.See related commentary by Alnajjar and Sweasy, p. 3459. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32312836     DOI: 10.1158/0008-5472.CAN-19-0883

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells.

Authors:  Stella Karsten; Roland Fiskesund; Xing-Mei Zhang; Petra Marttila; Kumar Sanjiv; Therese Pham; Azita Rasti; Lars Bräutigam; Ingrid Almlöf; Maritha Marcusson-Ståhl; Carolina Sandman; Björn Platzack; Robert A Harris; Christina Kalderén; Karin Cederbrant; Thomas Helleday; Ulrika Warpman Berglund
Journal:  Cell Death Differ       Date:  2022-01       Impact factor: 15.828

2.  Biomarkers of nucleic acid oxidation - A summary state-of-the-art.

Authors:  Mu-Rong Chao; Mark D Evans; Chiung-Wen Hu; Yunhee Ji; Peter Møller; Pavel Rossner; Marcus S Cooke
Journal:  Redox Biol       Date:  2021-01-28       Impact factor: 11.799

3.  Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma.

Authors:  Morten P Oksvold; Ulrika Warpman Berglund; Helge Gad; Baoyan Bai; Trond Stokke; Idun Dale Rein; Therese Pham; Kumar Sanjiv; Geir Frode Øy; Jens Henrik Norum; Erlend B Smeland; June H Myklebust; Thomas Helleday; Thea Kristin Våtsveen
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

4.  Disrupted mitochondrial homeostasis coupled with mitotic arrest generates antineoplastic oxidative stress.

Authors:  Xiaohe Hao; Wenqing Bu; Guosheng Lv; Limei Xu; Dong Hou; Jing Wang; Xiaojie Liu; Tingting Yang; Xiyu Zhang; Qiao Liu; Yaoqin Gong; Changshun Shao
Journal:  Oncogene       Date:  2021-11-12       Impact factor: 9.867

5.  TH588 and Low-Dose Nocodazole Impair Chromosome Congression by Suppressing Microtubule Turnover within the Mitotic Spindle.

Authors:  Girish Rajendraprasad; Susana Eibes; Claudia Guasch Boldú; Marin Barisic
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.